Berg J, Weinstein M J, Springfield D S, Rand W M
Department of Surgery, School of Veterinary Medicine, Tufts University, North Grafton, MA 01536, USA.
J Am Vet Med Assoc. 1995 May 15;206(10):1555-60.
Thirty-five dogs with appendicular osteosarcoma were treated with 5 doses of doxorubicin (30 mg/m2 of body surface, i.v., every 2 weeks). Surgical excision of the primary tumor was performed 13 days after the second (n = 18) or third (n = 17) treatment, and the subsequent doxorubicin treatment was given the day following surgery. Resected tumors were evaluated histologically to determine response to preoperative chemotherapy (ie, percentage of the tumor that was necrotic). Survival data for the 35 dogs were compared with survival data for a historical control group, consisting of 162 dogs with appendicular osteosarcoma treated by amputation alone. Administration of doxorubicin at 2 week intervals was well tolerated. Three dogs were alive and did not have evidence of disease at the time of reporting. Of the remaining 32 dogs, 3 died or were euthanatized because of cardiomyopathy presumably caused by doxorubicin; 1 died suddenly 116 weeks after initiation of treatment; and the remaining 28 were euthanatized because of problems documented to be related to distant metastases. Thirteen dogs (40.6%) were euthanatized because of pulmonary metastases, 10 dogs (31.3%) were euthanatized because of bone metastases, and 5 dogs (15.6%) were euthanatized because of metastases in other sites. The proportion of dogs euthanatized because of bone metastases was significantly (P < 0.001) higher for the study group than for the control group. Median survival time for the 35 dogs that received doxorubicin was estimated to be 52.3 weeks, and 1- and 2-year survival rates were estimated to be 50.5 and 9.7%, respectively. Survival time was significantly (P < 0.0001) longer for these dogs than for control dogs.(ABSTRACT TRUNCATED AT 250 WORDS)
35只患有附肢骨肉瘤的犬接受了5剂阿霉素治疗（30mg/m²体表面积，静脉注射，每2周一次）。在第二次（n = 18）或第三次（n = 17）治疗后13天进行原发性肿瘤的手术切除，术后当天给予后续阿霉素治疗。对切除的肿瘤进行组织学评估，以确定对术前化疗的反应（即坏死肿瘤的百分比）。将这35只犬的生存数据与一个历史对照组的生存数据进行比较，该对照组由162只仅接受截肢治疗的附肢骨肉瘤犬组成。每2周间隔给予阿霉素耐受性良好。在报告时，3只犬存活且无疾病迹象。其余32只犬中，3只因可能由阿霉素引起的心肌病死亡或实施安乐死；1只在治疗开始116周后突然死亡；其余28只因记录到的与远处转移相关的问题实施安乐死。13只犬（40.6%）因肺转移实施安乐死，10只犬（31.3%）因骨转移实施安乐死，5只犬（15.6%）因其他部位转移实施安乐死。研究组因骨转移实施安乐死的犬的比例显著高于对照组（P < 0.001）。接受阿霉素治疗的35只犬的中位生存时间估计为52.3周，1年和2年生存率分别估计为50.5%和9.7%。这些犬的生存时间显著长于对照犬（P < 0.0001）。（摘要截短至250字）
